Insys Therapeutics (INSY) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Insys Therapeutics (NASDAQ:INSY) released its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.08), Morningstar.com reports. Insys Therapeutics had a negative net margin of 238.31% and a negative return on equity of 130.43%. The business had revenue of $18.30 million during the quarter, compared to analyst estimates of $24.05 million. During the same quarter last year, the company posted ($2.30) earnings per share. The company’s revenue was down 40.4% on a year-over-year basis.

Insys Therapeutics stock traded up $0.23 during trading hours on Wednesday, reaching $7.77. 19,479 shares of the stock were exchanged, compared to its average volume of 388,011. The company has a market capitalization of $664.49 million, a price-to-earnings ratio of -15.39 and a beta of 1.67. Insys Therapeutics has a twelve month low of $4.90 and a twelve month high of $14.00.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its holdings in shares of Insys Therapeutics by 7.9% in the second quarter. BlackRock Inc. now owns 2,637,505 shares of the specialty pharmaceutical company’s stock worth $19,096,000 after acquiring an additional 193,740 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Insys Therapeutics by 10.1% in the second quarter. Northern Trust Corp now owns 348,334 shares of the specialty pharmaceutical company’s stock worth $2,522,000 after acquiring an additional 32,009 shares during the last quarter. Millennium Management LLC bought a new position in shares of Insys Therapeutics in the second quarter worth about $1,232,000. Schwab Charles Investment Management Inc. lifted its holdings in shares of Insys Therapeutics by 33.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 126,335 shares of the specialty pharmaceutical company’s stock worth $915,000 after acquiring an additional 31,840 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new position in shares of Insys Therapeutics in the third quarter worth about $969,000. Hedge funds and other institutional investors own 18.04% of the company’s stock.

Several equities analysts recently commented on the stock. Zacks Investment Research upgraded shares of Insys Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 11th. ValuEngine upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. Jefferies Financial Group reiterated a “buy” rating and set a $10.00 price objective on shares of Insys Therapeutics in a research note on Friday, August 10th. Piper Jaffray Companies set a $4.00 price objective on shares of Insys Therapeutics and gave the stock a “sell” rating in a research note on Saturday, August 11th. Finally, Royal Bank of Canada reiterated a “buy” rating and set a $9.00 price objective on shares of Insys Therapeutics in a research note on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $7.67.

COPYRIGHT VIOLATION WARNING: “Insys Therapeutics (INSY) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS” was originally published by WKRB News and is the property of of WKRB News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.wkrb13.com/2018/11/07/insys-therapeutics-insy-releases-quarterly-earnings-results-misses-estimates-by-0-08-eps.html.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

Featured Article: Dow Jones Industrial Average (DJIA)

Earnings History for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply